Department of Internal Medicine, Division of Vascular Medicine and Hemostaseology, Johann Wolfgang Goethe-University Hospital, Frankfurt/Main, Germany.
Thromb J. 2013 Nov 1;11(1):22. doi: 10.1186/1477-9560-11-22.
To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific coagulation factors has already entered the market, and new indications for DOA will be released each year over the next few years. Due to their heterogeneous mode of action and different pharmacokinetic profile each DOA will vary in its effects on coagulations assays, and it is of current importance to recognize these variable effects.In this summary the main considerable factors for correct laboratory test interpretation under DOA treatment are described.
为了避免误解和管理不当,临床医生应该了解新型直接口服抗凝剂(DOA)对凝血检测的干扰。针对特定凝血因子的各种口服抗凝剂已经上市,并且在未来几年中每年都会有新的 DOA 适应证发布。由于它们的作用机制不同,药代动力学特征也不同,因此每种 DOA 对凝血检测的影响也不同,因此目前重要的是要认识到这些可变的影响。在本摘要中,描述了在 DOA 治疗下正确进行实验室检测解读的主要考虑因素。